234 related articles for article (PubMed ID: 35304457)
21. Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
Sun F; McCoach CE
Curr Treat Options Oncol; 2021 Jun; 22(8):72. PubMed ID: 34165651
[TBL] [Abstract][Full Text] [Related]
22. NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake.
Lee YA; Lee H; Im SW; Song YS; Oh DY; Kang HJ; Won JK; Jung KC; Kwon D; Chung EJ; Hah JH; Paeng JC; Kim JH; Choi J; Kim OH; Oh JM; Ahn BC; Wirth LJ; Shin CH; Kim JI; Park YJ
J Clin Invest; 2021 Sep; 131(18):. PubMed ID: 34237031
[TBL] [Abstract][Full Text] [Related]
23. A Case Report of Poor Response to Selpercatinib in the Presence of a 632_633 RET Deletion.
Wijewardene A; Bastard K; Wang B; Gild M; Luxford C; Gill A; Robinson B; Bullock M; Clifton-Bligh R
Thyroid; 2023 Jan; 33(1):119-125. PubMed ID: 36416226
[No Abstract] [Full Text] [Related]
24. Selpercatinib: First Approval.
Markham A
Drugs; 2020 Jul; 80(11):1119-1124. PubMed ID: 32557397
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant selpercatinib for advanced medullary thyroid cancer.
Jozaghi Y; Zafereo M; Williams MD; Gule-Monroe MK; Wang J; Grubbs EG; Vaporciyan A; Hu MI; Busaidy N; Dadu R; Waguespack SG; Subbiah V; Cabanillas M
Head Neck; 2021 Jan; 43(1):E7-E12. PubMed ID: 33169506
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.
Heilmann AM; Subbiah V; Wang K; Sun JX; Elvin JA; Chmielecki J; Sherman SI; Murthy R; Busaidy NL; Subbiah I; Yelensky R; Nangia C; Vergilio JA; Khan SA; Erlich RL; Lipson D; Ross JS; Miller VA; Shah MH; Ali SM; Stephens PJ
Oncology; 2016; 90(6):339-46. PubMed ID: 27207748
[TBL] [Abstract][Full Text] [Related]
27. Selpercatinib and capmatinib combination promotes sustained complete response in novel
Leite CA; Carvalho RP; da Costa FM; Medeiros AK; Schutz FA; William WN
Front Oncol; 2023; 13():1264231. PubMed ID: 37876974
[No Abstract] [Full Text] [Related]
28. Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET-rearranged thyroid cancer.
Raman R; Villefranc JA; Ullmann TM; Thiesmeyer J; Anelli V; Yao J; Hurley JR; Pauli C; Bareja R; Wha Eng K; Dorsaint P; Wilkes DC; Beg S; Kudman S; Shaw R; Churchill M; Ahmed A; Keefer L; Misner I; Nichol D; Gumpeni N; Scognamiglio T; Rubin MA; Grandori C; Solomon JP; Song W; Mosquera JM; Dephoure N; Sboner A; Elemento O; Houvras Y
J Exp Med; 2022 Jun; 219(6):. PubMed ID: 35510953
[TBL] [Abstract][Full Text] [Related]
29. Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors.
Khatri U; Dayal N; Hu X; Larocque E; Naganna N; Shen T; Liu X; Holtsberg FW; Aman MJ; Sintim HO; Wu J
Mol Cancer Ther; 2023 Jun; 22(6):717-725. PubMed ID: 37070927
[TBL] [Abstract][Full Text] [Related]
30. Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated
Solomon BJ; Zhou CC; Drilon A; Park K; Wolf J; Elamin Y; Davis HM; Soldatenkova V; Sashegyi A; Lin AB; Lin BK; F Loong HH; Novello S; Arriola E; Pérol M; Goto K; Santini FC
Future Oncol; 2021 Mar; 17(7):763-773. PubMed ID: 33150799
[TBL] [Abstract][Full Text] [Related]
31. Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer.
Subbiah V; Gouda MA; Iorgulescu JB; Dadu R; Patel K; Sherman S; Cabanillas M; Hu M; Castellanos LE; Amini B; Meric-Bernstam F; Shen T; Wu J
NPJ Precis Oncol; 2024 Mar; 8(1):62. PubMed ID: 38438731
[TBL] [Abstract][Full Text] [Related]
32. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment.
Dabelić N; Jukić T; Fröbe A
Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884
[TBL] [Abstract][Full Text] [Related]
33. Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancers.
Sarvestani AL; Lambdin J; Hu M; Cabanillas M; Waguespack SG; Hernandez JM; Zafereo ME
Ann Surg Oncol; 2024 Apr; 31(4):2202-2203. PubMed ID: 38245643
[No Abstract] [Full Text] [Related]
34. State-of-the-Art Strategies for Targeting
Subbiah V; Yang D; Velcheti V; Drilon A; Meric-Bernstam F
J Clin Oncol; 2020 Apr; 38(11):1209-1221. PubMed ID: 32083997
[TBL] [Abstract][Full Text] [Related]
35. Drug resistance profiles of mutations in the RET kinase domain.
Liu X; Shen T; Mooers BHM; Hilberg F; Wu J
Br J Pharmacol; 2018 Sep; 175(17):3504-3515. PubMed ID: 29908090
[TBL] [Abstract][Full Text] [Related]
36. Hallmarks of RET and Co-occuring Genomic Alterations in
Adashek JJ; Desai AP; Andreev-Drakhlin AY; Roszik J; Cote GJ; Subbiah V
Mol Cancer Ther; 2021 Oct; 20(10):1769-1776. PubMed ID: 34493590
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of Selpercatinib in
Drilon A; Oxnard GR; Tan DSW; Loong HHF; Johnson M; Gainor J; McCoach CE; Gautschi O; Besse B; Cho BC; Peled N; Weiss J; Kim YJ; Ohe Y; Nishio M; Park K; Patel J; Seto T; Sakamoto T; Rosen E; Shah MH; Barlesi F; Cassier PA; Bazhenova L; De Braud F; Garralda E; Velcheti V; Satouchi M; Ohashi K; Pennell NA; Reckamp KL; Dy GK; Wolf J; Solomon B; Falchook G; Ebata K; Nguyen M; Nair B; Zhu EY; Yang L; Huang X; Olek E; Rothenberg SM; Goto K; Subbiah V
N Engl J Med; 2020 Aug; 383(9):813-824. PubMed ID: 32846060
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of RET-Specific Kinase Inhibitors in RET-Altered Cancers: A Systematic Review.
Ali MA; Shah SS; Ali R; Bajwa SF; Rehman S; Anwar A; Anwar MY; Saeed M; Mirza N; Aiman W
Cancer Invest; 2023 Sep; 41(8):739-749. PubMed ID: 37782113
[TBL] [Abstract][Full Text] [Related]
39. Emergence of High Level of MET Amplification as Off-Target Resistance to Selpercatinib Treatment in KIF5B-RET NSCLC.
Zhu VW; Madison R; Schrock AB; Ou SI
J Thorac Oncol; 2020 Jul; 15(7):e124-e127. PubMed ID: 32593453
[No Abstract] [Full Text] [Related]
40. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
